2026 Clinical Trial Supply Insight

Through a combination of structured ranking questions, qualitative responses and insights from a poll of industry colleagues, the survey highlights the operational pressures and structural shifts shaping clinical trial supply today.

Across packaging, labeling, sourcing, distribution and investigational site operations, a consistent signal emerges: execution speed and operational flexibility are now baseline – and rising – expectations across clinical supply activities.

Respondents point to increasing regulatory requirements, supply constraints, rising drug costs and expanding global trials as key forces influencing supply-chain decision making.

While the number of respondents remains limited, the convergence of signals across multiple topics reveals several directional trends likely to shape clinical supply strategies in 2026, including faster and more adaptable supply models, greater cost control and supply predictability, as well as the need to ensure supply continuity and reduce site burden.

Specific insights covered in this report

The following sections present the key insights across clinical trial supply. They highlight priorities and challenges shaping 2026.

Clinical Supply Chain Priorities for 2026
Clinical Packaging, Labeling & Distribution – 2026 Outlook
Drug & Ancillary Sourcing – 2026 Outlook
Investigational Site Challenges – 2026 Outlook

In the Myonex 2026 Trend survey, respondents were asked to rank the following clinical supply-chain priorities from most to least critical for their organization as we started 2026.

1 Immediate Operational Priority: Reducing Supply Delays

Across all analytical views, reducing supply delays clearly emerges as the most critical priority for 2026. The data show a consistent signal:

Clinical Supply – 2026 Top priority signal

This chart highlights how respondents prioritize clinical supply-chain objectives for 2026 based on weighted scoring. It provides a clear view of which priorities are perceived as most critical across organizations.

Most Critical Supply Chain Priority in 2026 in Your Organization

This reflects a strong industry concern: ensuring timely supply execution is perceived as the most immediate operational challenge for clinical trial supply organizations in 2026.

2 Execution Control Priorities: Cost, Flexibility and Supply Visibility

A second cluster of priorities reflects the need to maintain control over increasingly complex clinical supply chains.

Three themes consistently stand out in the ranking analysis, each appearing frequently among Top-3 mentions and achieving strong weighted scores.Based on the Top-3 mentions, they rank as follows:

• Controlling costs
• Flexibility to support hybrid or decentralized trials
• Supply visibility & predictability

Together, these priorities highlight the growing importance of operational control and adaptability, as organizations navigate rising drug costs, evolving trial models, and increasing supply-chain complexity.

It reflects a strong need for predictable, flexible, and cost-controlled supply operations.

Key Insight

Taken together, the results suggest that clinical supply leaders are primarily focused on ensuring reliable execution and operational control, before pursuing broader structural transformations of their supply-chain models.

Respondents were asked to identify the expectations and challenges they foresee for clinical packaging and labeling as we approach 2026, including timelines, complexity, flexibility, innovation, multilingual requirements, regulatory changes, and digital labeling.

1 Overarching Signal: Speed + Flexibility Are Non-Negotiable

Across regions and organization sizes, and spanning both packaging and labeling challenges, one dominant signal emerges: execution speed and operational flexibility have become baseline expectations for 2026.
Sponsors explicitely expect:

A quick poll of industry colleagues reinforces this signal, with “Reduce supply delays” emerging as the most critical expectation for clinical packaging and labeling, followed by multilingual label compliance and preparing for digital labeling, while adapting to regulatory changes was selected less frequently.

2 Packaging: Agility Under Capacity Constraints

Beyond speed, contributors point to increasing structural pressure:

Several pharma organizations emphasize slot access as key expectation from packaging partners. This suggests that by 2026, packaging performance may depend not only on process efficiency but also on secured execution capacity.

3 Different Risk Lenses

While speed and flexibility emerge as common expectations for clinical packaging and labeling, respondents also reveal different approaches to managing supply risk. Some organizations emphasize highly adaptive supply models to respond quickly to evolving trial conditions, while others prioritize robust frameworks designed to ensure reliable execution at scale.

4 Labeling: Regulatory & Multilingual Complexity Intensifies

These responses suggest that distribution reliability remains a foundational expectation, particularly in an increasingly complex global trial environment.

Labeling expectations for 2026 are shaped by regulatory volatility and geographic expansion.

Labeling is increasingly seen as a timeline driver – not an administrative afterthought.

5 Digital Labeling: Strategic Interest, Operational Caution

Digital labeling is frequently mentioned across regions. However, respondents express mixed expectations:

• Recognized as potentially transformative
• Not universally expected to mature by 2026: Regulatory readiness remains uncertain, concerns around cost and adoption, and accessibility considerations

Digital labeling appears to be a structural shift in preparation, but not yet a fully stabilized execution model.

Emerging 2026 Clinical Packaging & Labeling Dynamic

The core tension shaping 2026 appears to be: Sponsors expect faster execution in a more regulated, more global, and more capacity-constrained environment.

Clinical Distribution

As clinical trials become more global and operationally complex, distribution is emerging as a critical factor in ensuring reliable clinical supply. Respondents highlighted several priorities and obstacles expected to shape clinical trial distribution in 2026, including logistics reliability, cold chain management, customs complexity, and risk mitigation.

1 Reliability and Risk Mitigation as Core Distribution Priorities

Across participants, logistics reliability and risk mitigation emerge as central priorities for clinical distribution in 2026. Several respondents explicitly mention:

These responses suggest that distribution reliability remains a foundational expectation, particularly in an increasingly complex global trial environment.

2 Customs, Tariffs and Cross-Border Complexity

A recurring theme across both Europe and North America sponsors and CROs is the growing impact of customs processes, tariffs, and import duties. Respondents mention:

Some respondents also note that tariffs and customs constraints may make certain global shipping strategies less attractive.

These factors indicate that cross-border regulatory and fiscal considerations are becoming increasingly influential in distribution planning.

3 Cold Chain Capacity and Temperature-Controlled Logistics

Several survey participants highlight temperature-controlled logistics as a key operational priority. Specific cold-chain management concerns include:

• Supply chain safety for temperature-sensitive products
• Cold and frozen storage capacity

These responses suggest that as clinical trials increasingly involve biologics, cell therapies, or temperature-sensitive materials, robust cold chain infrastructure remains critical to distribution success.

4 Timelines and Operational Execution

Distribution timelines are mentioned by multiple contributors, including:

These operational constraints highlight the importance of efficient logistics coordination and distribution planning, particularly as trials expand globally.

5 Operational Complexity: Systems Integration & Global Study Expansion

Some responses point to operational complexity linked to global trial management. Examples include:

• Integration between RTSM systems and ERP systems to enable automated processing of shipping orders
• The ability to rapidly activate new countries, particularly in Asia and Latin America

These responses suggest that technology integration and scalability will be increasingly critical to support global distribution networks.

6 Additional Emerging Considerations

A few additional signals appear in the responses:

• Patient-centric distribution models
• Sustainability considerations in supply chain planning

While mentioned less frequently, these themes indicate evolving expectations around distribution design.

Directional Insight for Clinical Distribution in 2026

Taken together, these responses suggest that clinical trial distribution in 2026 may be shaped by:

Overall, distribution strategies may increasingly need to balance global reach, regulatory compliance, and operational reliability in an environment of expanding clinical trial complexity.

Drug Sourcing

Respondents were asked to identify the emerging challenges and shifts they foresee in drug sourcing as we approach 2026, including comparator and commercial drug sourcing

1 Overarching Signal: Availability and Lead Times Remain Structural Constraints

Across both Europe and North America, drug availability and long lead times emerge as the dominant concern heading into 2026. Respondents report:

One respondent explicitly notes that maintaining access to certain drugs (particularly in oncology) over 2-6 year studies is becoming increasingly difficult.

2 Cost Pressure & Tariff Exposure Are Rising

Both survey and poll responses align with this signal: “Cost-related concerns”, “Cost and potential tariffs”, “Cost increases (e.g., MFN impacts)” and “Need to source from low-cost markets with full documentation”.

Cost control is therefore not an isolated financial issue; it is directly linked to sourcing strategy, geography, and documentation compliance.

3 Local vs Central Sourcing: Toward Hybrid Flexibility

A recurring structural theme is the growing debate between:

• Central sponsor-led sourcing
• Local sourcing by investigational sites or pharmacies
• Hybrid models combining both approaches

Some respondents anticipate alternative sourcing strategies beyond traditional bulk procurement. These may include hybrid models allowing local sourcing where needed, or sponsor-supplied approaches for selected sites (e.g., “white glove” supply).

One respondent also notes that protocols may increasingly need to allow sourcing flexibility, for example by permitting generics or alternative supply strategies when availability becomes constrained.

The poll of industry colleagues further indicates interest in on-demand sourcing models, suggesting that some sponsors are exploring more flexible approaches to sourcing.

Overall, these signals suggest that sourcing strategies may become less strictly centralized and more adaptable depending on study and market conditions, reflecting a growing expectation for sourcing models that can better respond to evolving trial requirement.

4 Documentation & Regulatory Complexity

Several respondents stress expectations and concerns about:

• Comparator sourcing reliable supply with appropriate and complete documentation
• Import sourcing constraints: customs and cross-border complexities

Ancillary Sourcing

Survey participants were asked to identify the trends and bottlenecks they expect in ancillary sourcing for clinical trials.

1 Availability & Stockouts Mirror Drug Sourcing Pressures

Responses point to availability challenges similar to those observed in drug sourcing. Respondents report:
 

Some respondents also highlight the need to anticipate sourcing earlier to mitigate material shortages, while operational timelines remain tight.

Ancillary supply appears increasingly exposed to the same market fragility affecting drug sourcing.

2 Product Compatibility & Qualification Complexity

Contributors highlight:

• Product compatibility testing requirements
• The need to quickly assess compatible ancillaries across trial countries
• Regulatory and procurement challenges in certain regions

These factors may create operational bottlenecks under compressed timelines.

3 Shelf-Life Constraints and Planning Pressure

Short shelf-life is listed as a major challenge in ancillary sourcing.
Limited shelf-life can increase planning pressure, as materials may need to be sourced closer to study timelines while still ensuring availability and compatibility across sites. This constraint reinforces the importance of careful planning and coordination between sourcing timelines and trial execution requirements.

4 Scope Expansion: What Should Sponsors Supply?

While expectations for patient-centric solutions in ancillary sourcing are mentioned, one large biotech respondent raises a structural question:

“Should sponsors supply only what is strictly required to deliver the drug, or a broader set of equipment that sites may need (e.g., freezers, centrifuges, laptops)?”

This reflects a broader shift toward patient-centric and site-centric supply strategies.

Consolidated 2026 Drug & Ancillary Sourcing Directional Insight

If these limited but consistent signals extend beyond this panel, 2026 sourcing trends may be characterized by:
 

The structural tension shaping 2026 appears to be: Sponsors must secure reliable, compliant, and cost-controlled supply in an environment of constrained availability, regulatory complexity, and evolving sourcing models.

1 Site Bandwidth and Operational Burden

Several respondents highlight site workload and limited bandwidth as a key challenge. Examples mentioned include:

• Large oncology sites managing hundreds of concurrent studies
• Staffing shortages
• Complex and process-driven workflows

In this context, respondents note that sites often have limited flexibility and may struggle to absorb additional operational requirements. Simplification of processes and reduction of site burden therefore appear increasingly important.

2 Storage Capacity & Operational Constraints

Storage limitations are repeatedly cited as a challenge for investigational sites.
That suggests that site infrastructure and storage capacity remain critical operational considerations, particularly as clinical trials increasingly involve temperature-controlled products.

Directional Insight for Investigational Site Challenges in 2026

Responses suggest sites face increasing pressure from workload, infrastructure constraints and complex workflows, reinforcing the need to simplify supply processes and reduce site burden.